drugset / Trial / NCT05632133

The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

NCT05632133

Phase 3 Completed 200 enrolled Kafrelsheikh University
RandomizedParallel-groupOpen-labelTreatment

Summary

We assessed serum CGRP concentrations before and after treatment in two hundred episodic migraine patients according to the International Classification of Headache Disorders 3rd edition, aged 10-55 years. We divided them into two groups first one received Ibuprofen 200-400 mg as a treatment for acute migraine attacks and lacosamide 50 mg Bid for 3 months, and the other group received only Ibuprofen 200-400 mg as a treatment for acute migraine attacks.

Timeline

Start
2022-06-01
Primary completion
2023-08-09
Completion
2023-08-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 50 mg Oral
Background Ibuprofen Small molecule 400 mg

Indications